Neuropulsas is a private clinic in Vilnius that provides repeated transcranial magnetic stimulation (rTMS), a non‑invasive, FDA‑ and CE‑cleared neuromodulation therapy for treatment‑resistant depression, anxiety, OCD, chronic pain, migraine and related conditions. Using MagVenture equipment, the clinic delivers brief, outpatient sessions tailored to each patient’s diagnosis, allowing rapid integration into daily life without surgery or anesthesia.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients with depression, anxiety, OCD, chronic pain, migraine, or other neuropsychiatric conditions do not achieve sufficient relief from medication or psychotherapy, and access to advanced neuromodulation treatments is limited in Lithuania.
Solution
Neuropulsas offers repeated transcranial magnetic stimulation (rTMS) as a non‑invasive, clinically validated neuromodulation therapy for a range of mental health and chronic pain disorders. The clinic uses FDA‑ and CE‑cleared MagVenture equipment, which delivers precisely targeted magnetic pulses to specific cortical regions to rebalance neural activity. Treatment sessions are brief, outpatient, and do not require anesthesia or hospitalization, allowing patients to resume daily activities immediately. Individualized treatment protocols are designed by qualified clinicians based on each patient’s diagnosis and response, and can be combined with psychotherapy or medication. The service is provided in a private, modern facility in Vilnius, making advanced rTMS accessible without referral to foreign centers.
Target Audience
Primary customers are adults in Lithuania seeking effective treatment for treatment‑resistant depression, anxiety, OCD, chronic pain, migraine, or related neuropsychiatric conditions, as well as clinicians referring patients for advanced neuromodulation therapy.
Features
- FDA and CE certified MagVenture rTMS system with high‑precision coil positioning for targeted cortical stimulation
- Fully non‑invasive protocol: no surgery, anesthesia, or inpatient stay; patients remain fully conscious
- Customizable stimulation parameters (frequency, intensity, session count) tailored to specific disorders such as depression, OCD, chronic pain, migraine, insomnia, and burnout
- Short treatment sessions (typically 20‑30 minutes) enabling easy integration into patients’ daily schedules
- Clinician‑guided assessment and monitoring, with the option to combine rTMS with psychotherapy or pharmacotherapy
- Proven efficacy rates of 60‑80 % in clinical studies, with observable improvements after 15‑20 sessions for depression and 5‑10 sessions for chronic pain